# Luis Paz‐Ares

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/luis-paz-ares/

## Facts

| Field | Value |
| --- | --- |
| Citations | 96,159 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 119 |
| i10-index | 520 |
| Last Known Institution | Hospital Universitario 12 De Octubre |
| OpenAlex ID | https://openalex.org/A5052765751 |
| ORCID iD | https://orcid.org/0000-0002-1947-3364 |
| Works | 1,378 |

## Researcher papers

Showing 12 of 35.

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Lung cancer: current therapies and new targeted treatments](https://scholariq.org/papers/lung-cancer-current-therapies-and-new-targeted-treatments/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-advanced-non-small-cell-lung-cancer/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://scholariq.org/papers/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Hospital Universitario 12 De Octubre](https://scholariq.org/institutions/hospital-universitario-12-de-octubre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.